Dyadic International, Inc. (DYAI)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Dyadic International, Inc.
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 463K | 350K | 236K | 624K |
| Gross Profit | -150K | -674K | -149K | -168K |
| Operating Income | -1.7M | -1.9M | -1.5M | -1.9M |
| Net Income | -1.8M | -2.0M | -1.6M | -2.0M |
| Diluted EPS | $-0.06 | $-0.06 | $nan | $-0.05 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 2.9M | 2.9M | 3.5M | 1.2M |
| Gross Profit | 807K | 923K | 2.3M | -1.1M |
| Operating Income | -10.1M | -8.2M | -5.9M | -7.1M |
| Net Income | -9.7M | -6.8M | -5.8M | -7.4M |
| Diluted EPS | $-0.34 | $-0.24 | $-0.20 | $-0.23 |